Company Overview of MORPHOTEK INC.
MORPHOTEK INC. develops a pipeline of preclinical and clinical stage monoclonal antibodies to treat cancer, inflammation, and infectious diseases. Its pipeline of products include Farletuzumab, an investigational monoclonal antibody that targets folate receptor alpha; Amatuximab, a monoclonal antibody that targets mesothelin; MORAb-004, an investigational monoclonal antibody that targets endosialin, MORAb-022, an investigational monoclonal antibody that targets a proinflammatory; and MORAb-066, an investigational monoclonal antibody that targets tissue factor. The company’s products are used to treat ovarian cancer, nonsmall cell lung cancer, melanoma, colorectal carcinoma, sarcoma, mesothel...
210 Welsh Pool Road
Exton, PA 19341
Founded in 1999
Key Executives for MORPHOTEK INC.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Chief Finance Officer and Vice President of Project Management
Executive Director of Marketing and Executive Director of Business Development
Vice President of Pilot Plant Operations
Compensation as of Fiscal Year 2014.
MORPHOTEK INC. Key Developments
Morphotek, Inc. Announces Initiation Of Farletuzumab Study in Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels of The Immunosuppressive CA125 Tumor Antigen
Mar 30 15
Morphotek Inc. announced that it has enrolled the first patient in a randomized, double-blind study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer with low levels of the immunosuppressive CA125 tumor antigen. The study will evaluate the efficacy and safety of farletuzumab, a monoclonal antibody that specifically binds to folate receptor-alpha (FRA), when combined with standard chemotherapy regimens carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD). The 003-011 follow-on study design is based on the results of pre-specified subgroup analyses of the completed 1,100 patient FAR-131 Phase 3 study. It is a randomized, double-blind, placebo-controlled trial to determine if farletuzumab improves the progression-free survival of platinum-sensitive ovarian cancer patients with low levels of CA125 using a modified farletuzumab dosing regimen to increase farletuzumab exposure. All patients will receive one of the initial standard-of-care chemotherapy regimens for six cycles combined with either farletuzumab or placebo, followed by maintenance therapy with the single assigned test article. Secondary objectives include evaluating overall survival, response rate, and safety. Morphotek expects to enroll 210 patients in this study, which will be conducted in sites across the United States, Japan, and Europe. Farletuzumab is a monoclonal antibody (mAb) that binds to the folate receptor-alpha (FRA), a folate binding protein that is expressed on ovarian and several other epithelial cancer cells. Monoclonal antibodies, a type of immunotherapy used to treat cancer, are laboratory-generated versions of immune system proteins and can be designed to attack a specific part of a cancer cell. Immunotherapy drugs offer a method of treatment separate from chemotherapy.
MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Stealth Biologics Announces Research Collaboration with Morphotek
Jul 15 14
Stealth Biologics LLC has announced a research collaboration with Morphotek, Inc. Under terms of the agreement, Stealth Biologics will use its protein design and optimization algorithms to engineer deimmunized biologics for application in cancer therapy. Morphotek will retain the right to develop and commercialize all deimmunized therapeutics resulting from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|